Charles River and ASC Therapeutics expand gene therapy manufacturing agreement

By Rachel Arthur

- Last updated on GMT

Pic: getty/svetlanakrivenceva
Pic: getty/svetlanakrivenceva

Related tags Charles river laboratories Gene therapy gene therapies Hemophilia Gene therapy candidate Manufacturing

Charles River Laboratories International and ASC Therapeutics have announced plans to manufacture ASC618, a second-generation gene therapy for hemophilia A.

ASC618 is designed to deliver a shortened but optimized version of the F8 gene to liver cells (the gene is mutated in people with Hemophilia A, preventing them from producing a blood clotting protein).

Currently in pre-clinical trials, the gene therapy from California-headquartered ASC has received IND clearance and Fast Track Designation from the US FDA. 

In addition, the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for an Orphan Medical Product Designation of ASC618.

New processes for AAV production and purification

ASC Therapeutics and Charles River have been working together since 2019 on GMP-virus manufacturing and have established processes for AAV production and purification.

“Together, Charles River and ASC Therapeutics have established a high-yield upstream process for AAV8 production, optimized the downstream purification methods to result in a more predictable drug product output, and fine-tuned a scalable manufacturing process in both upstream and downstream,”​ say the companies.

Charles River made a series of acquisitions in 2021, and the company says that through gaining Cognate BioServices, Cobra Biologics, and Vigene Biosciences it has enhanced its end-to-end CDMO capabilities. Its platforms now cover cell therapy, viral vector and plasmid DNA production.

Related news

Show more

Related product

Process optimization for mAb commercial manufacturing

Process optimization for mAb commercial manufacturing

Content provided by Catalent | 01-Jun-2023 | Product Presentation

Process characterization and validation is an important step in the product development journey and late-phase development, and it is required before transferring...